Disability and quality of life in patients with treatment-resistant schizophrenia on long- term clozapine therapy

Objectives: To assess disability and quality of life (QOL) in treatment resistant schizophrenia (TRS) on long term clozapine therapy and assess their correlation with positive, negative and cognitive symptoms. Methodology: Disability and QOL in forty patients with TRS (as per modified Kane's criteria) were assessed using World Health Organization Disability Assessment Schedule 2.0 and World Health Organization Quality of Life–BREF. Scale for assessment of positive symptoms, scale for assessment of negative symptoms and Addenbrooke's cognitive examination-III were used to assess positive, negative and cognitive symptoms. Medication adherence rating scale assessed medication adherence. Results: Disability and QOL correlated significantly with medication adherence, negative and cognitive symptoms but not with positive symptoms. Subgroup analysis revealed significant difference between medication adherence (good vs poor) and cognitive (impairment vs non-impairment) groups. Conclusion: Negative and cognitive symptoms, and medication adherence correlated with disability and QOL.

[1]  Farooq Naeem,et al.  The Cognitive Model of Negative Symptoms in Schizophrenia: A Hierarchical Component Model With PLS-SEM , 2021, Frontiers in Psychiatry.

[2]  N. Franck,et al.  Characteristics associated with self-reported medication adherence in persons with psychosis referred to psychosocial rehabilitation centers , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[3]  S. Grover,et al.  Effectiveness of clozapine on quality of life and functioning in patients with treatment-resistant schizophrenia , 2020, Nordic journal of psychiatry.

[4]  G. Fond,et al.  Adherence to Antipsychotic Medication and Quality of Life in Latin-American Patients Diagnosed with Schizophrenia , 2020, Patient preference and adherence.

[5]  Jian-Quan Shi,et al.  Comparative diagnostic accuracy of ACE-III and MoCA for detecting mild cognitive impairment , 2019, Neuropsychiatric disease and treatment.

[6]  Philip D. Harvey,et al.  Prediction of disability in schizophrenia: Symptoms, cognition, and self-assessment , 2019, Journal of Experimental Psychopathology.

[7]  Yumei Lv,et al.  The mediating effect of family function and medication adherence between symptoms and mental disability among Chinese patients with schizophrenia: a cross-sectional study , 2018, Psychology, health & medicine.

[8]  V. Siskind,et al.  Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis , 2017, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[9]  Abraham Weizman,et al.  Association between serum levels of glutamate and neurotrophic factors and response to clozapine treatment , 2017, Schizophrenia Research.

[10]  E. Flowers,et al.  Serum BDNF Is Positively Associated With Negative Symptoms in Older Adults With Schizophrenia , 2016, Biological research for nursing.

[11]  N. Hazari,et al.  Association of Clozapine with Seizures: A Brief Report Involving 222 Patients Prescribed Clozapine. , 2015, East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan.

[12]  K. Hashimoto,et al.  Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine , 2013, Neuroscience Letters.

[13]  H. Möller,et al.  World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance , 2012, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[14]  N. Nebhinani,et al.  Metabolic syndrome among patients receiving clozapine: A preliminary estimate , 2011, Indian journal of pharmacology.

[15]  Y. Kaneda,et al.  Quality of life and cognitive dysfunction in people with schizophrenia , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[16]  S. Eack,et al.  Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. , 2007, Schizophrenia bulletin.

[17]  B. Rath,et al.  Effectiveness Study of Typical and Atypical Antipsychotics on Patients with Schizophrenia using WHO Disability Assessment Schedule (WHODAS 2.0) , 2021, Biomedical and Pharmacology Journal.

[18]  B. Snitz,et al.  Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. , 1993, The American journal of psychiatry.